Medtronic has secured approval from the US Food and Drug Administration (FDA) for its Vanta device, a recharge-free implantable neurostimulator (INS).
With a device life of up to 11 years, Vanta comes with the potential to deliver nearly twice the device life compared to other primary cell devices.
This represents a 10% longer device life than the company’s last-generation recharge-free neurostimulator, PrimeAdvanced. Vanta is also 20% smaller compared to PrimeAdvanced.
The new device uses Medtronic’s AdaptiveStim technology to offer personalised pain relief that adjusts to a patient’s movement or body position via an in-built accelerometer.
AdaptiveStim technology can automatically adjust stimulation to continue the optimal dose for individual patients.
Using Medtronic SureScan technology, Vanta also offers full-body MRI access.
Interventional pain management physician Krishnan Chakravarthy said: “Not every patient with chronic, intractable pain is an ideal candidate for a rechargeable device, so the Vanta INS represents a welcome addition to my portfolio of available treatment options.
“The extended battery life, broad MRI compatibility and personalised relief through AdaptiveStim technology allow for a more hassle-free experience and greater freedom for my patients as we manage their chronic pain.”
The new device also enables access to Snapshot, the company’s data insights solution, which provides clinicians with objective reporting of patient activity levels.
Medtronic stated that the clinicians and patients who intend to use the Vanta neurostimulator may also use CareGuidePro, a mobile application and web portal which acts as a patient guide throughout spinal cord stimulation therapy.
Currently, CareGuidePro is in limited commercial release and a full launch is planned later this year.
Medtronic pain therapies vice-president and general manager Charlie Covert said: “For those who prefer or require a recharge-free device, I believe the Vanta neurostimulator offers the best hardware and features available today.”
Recently, the company secured FDA approval for its SenSight Directional Lead System for deep brain stimulation (DBS) treatment.